

Australia launches first clinical and commercial-scale viral vector manufacturing facility

03 November 2025 | News

Backed by a \$134.5 million investment from the NSW Government



Australia's first and only clinical and commercial-scale viral vector Contract Development and Manufacturing Organisation (CDMO), has officially opened in Sydney. This milestone marks a major step forward in strengthening Australia's sovereign capabilities in advanced biomanufacturing.

Located within the Westmead Health and Innovation Precinct, the largest health, education, research, and innovation precinct in the country, VVMF is backed by a \$134.5 million investment from the New South Wales (NSW) Government. The facility supports both state and national priorities to grow high-value jobs, boost exports, and attract international investment into NSW and Australia.

VVMF will deliver GMP-grade lentiviral (LV) and adeno-associated viral (AAV) vectors, supporting the development of transformative gene and cell therapies.

Services include:

- Vector research and development
- Construct design and optimisation
- Process development
- Pre-clinical and clinical manufacturing (up to 500L)
- Technology transfer
- Wraparound support leveraging Australia's R&D tax incentives, streamlined regulatory pathways, and world-class clinical trial infrastructure

Prof. Ian Alexander, Paediatrician and Chief Medical Officer, and Prof. Leszek Lisowski, vectrologist and Chief Technology

Officer, are the founding scientists for the business, bringing deep scientific and clinical expertise from concept to clinic.